RT Journal Article
SR Electronic
T1 Extensive brain structural heterogeneity in individuals with schizophrenia and bipolar disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.08.20095091
DO 10.1101/2020.05.08.20095091
A1 Thomas Wolfers
A1 Jaroslav Rokicki
A1 Dag Alnæs
A1 Ingrid Agartz
A1 Seyed Mostafa Kia
A1 Tobias Kaufmann
A1 Mariam Zabihi
A1 Torgeir Moberget
A1 Ingrid Melle
A1 Christian F Beckmann
A1 Ole A Andreassen
A1 Andre F Marquand
A1 Lars T Westlye
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.08.20095091.abstract
AB Identifying brain processes involved in the risk and development of mental disorders is a major aim. We recently reported substantial inter-individual heterogeneity in brain structural aberrations among patients with schizophrenia and bipolar disorder. Estimating the normative range of voxel-based morphometry (VBM) data among healthy individuals using a Gaussian Process Regression (GPR) enables us to map individual deviations from the healthy range in unseen datasets. Here we aim to replicate our previous results in an independent sample of patients with schizophrenia (n=166), bipolar disorder (n=135) and healthy individuals (n=687). In line with previous findings, our results revealed robust group level differences between patients and healthy controls, yet only a small proportion of patients with schizophrenia or bipolar disorder exhibited extreme negative deviations from the norm in the same brain regions. These direct replications support that group level-differences in brain structure disguise considerable individual differences in brain aberrations, with important implications for the interpretation and generalization of group-level brain imaging findings to the individual with a mental disorder.Competing Interest StatementO.A.A. is a consultant to HealthLytix and received speaker’s honorarium from Lundbeck. C.B. is shareholder of and director of SBG Neuro. The other authors declare that they have no competing interests.Funding StatementThe study is supported by the Research Council of Norway (223273, 249795, 298646, 300768, 276082), the South-Eastern Norway Regional Health Authority (2014097, 2015073, 2016083, 2019101), a Wellcome Trust Innovator award (‘BRAINCHART’, 215698/Z/19/Z), and the European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG Grant 802998 and Grant 847776). This work was performed on the TSD (Tjenester for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) with resources provided by UNINETT Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway. TW gratefully acknowledges the Niels Stensen Fellowship for supporting this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs the data is clinical data including patient information access is restricted in accordance with European and Norwegian law.